Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
About
About the Journal
Editorial board
The Publisher
Abstracting and indexing
Publication ethics
Privacy Statement
Contact
Policies
Open access policy
Editorial policies
Authors' self archiving and sharing policy
Commercial policies
Privacy policy
Guidelines
Guidelines for authors
Guidelines for Reviewers
Artwork guidelines
Publication fees
Archives
Current
Search
Register
Login
Submit now
Home
/
Archives
/
Vol. 9: January-December 2022
Vol. 9: January-December 2022
Published:
2022-01-25
Point of View
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
Pierluigi Russo
31-35
PDF
ePub
html
Original Research Article
Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
José Manuel Martínez-Sesmero, Borja Smith, Julen Madurga
68-72
PDF
ePub
html
Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis
Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto
58-67
PDF
ePub
html
Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)
Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni
45-57
PDF
ePub
html
Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution
Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti
36-44
PDF
ePub
html
Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations
Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia
22-29
PDF
ePub
html
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega
14-21
PDF
ePub
html
Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project
Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli, Maria Chiara Tisi
1-8
PDF
ePub
html
Short Communication
Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi
9-13
PDF
ePub
html
Erratum
Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
30
PDF
ePub
html
banners150